<DOC>
	<DOCNO>NCT00913744</DOCNO>
	<brief_summary>This study evaluate safety efficacy Ocriplasmin intravitreal injection , subject diagnose exudative AMD focal vitreomacular adhesion . Ultimately , believe intravitreal ocriplasmin may offer physician safe agent pharmacologic vitreolysis nonsurgical resolution focal vitreomacular adhesion AMD subject adhesion may causally associate bad prognosis ) .</brief_summary>
	<brief_title>Safety Efficacy Study Intravitreal Ocriplasmin Subjects With AMD With Focal Vitreomacular Adhesion</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>1 . Male female subject age &gt; 50 2 . Presence focal vitreomacular adhesion measure Optical Coherence Tomography ( OCT ) . 3 . Diagnosis active primary recurrent subfoveal CNV secondary AMD , include predominantly classic , minimally classic occult lesion classic component . 4 . The total area Choroidal Neovascularization ( CNV ) ( include classic occult component ) encompass within lesion must &gt; 50 % total lesion area 5 . The total lesion area must &lt; 12 disc area 6 . Subjects previously receive least three antiangiogenic injection ( Lucentis速 Avastin速 ) study eye . 7 . Subjects visual acuity 20/32 20/200 study eye 8 . Written inform consent obtain subject prior inclusion study 1 . Evidence complete macular Posterior Vitreous Detachment ( PVD ) study eye biomicroscopy , Bscan ultrasound OCT prior plan study drug injection 2 . Subjects vitreous haemorrhage precludes either follow : visualization posterior pole visual inspection adequate assessment macula either OCT and/or fluorescein angiography study eye opacity preclude visualisation fundus . 3 . Subjects previously receive 9 antiangiogenic agent injection ( whether Lucentis速 Avastin速 antiangiogenic agent ) study eye 4 . Subjects history rhegmatogenous retinal detachment proliferative vitreoretinopathy ( PVR ) study eye 5 . Subjects high myopia ( &gt; 8D ) aphakia study eye 6 . Subjects ocular surgery study eye prior three month 7 . Subjects vitrectomy study eye time .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>AMD</keyword>
</DOC>